Eric Easom is President, Chief Executive Officer and Board Chair of AN2 Therapeutics, Inc. (ANTX). The company reported total compensation of $1,382,985 for fiscal year 2025.
| Salary | $603,750 |
|---|---|
| Bonus | $0 |
| Stock awards | $164,133 |
| Option awards | $275,539 |
| Non-equity incentive plan | $332,063 |
| Pension and non-qualified deferred compensation | $0 |
| All other compensation | $7,500 |
| Total | $1,382,985 |
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed, without adjustment.
Cited to the compensation disclosure AN2 Therapeutics, Inc. filed April 22, 2026, accession 0001193125-26-170314.
| Named executive officer | Role | FY2025 total |
|---|---|---|
| Eric Easom this page | President, Chief Executive Officer and Board Chair | $1,382,985 |
| Josh Eizen | Chief Legal Officer and Chief Operating Officer | $807,080 |
| Lucy Day | Chief Financial Officer | $774,336 |
The company's named executive officers for fiscal year 2025, and what it reported for each. See the full AN2 Therapeutics, Inc. compensation brief.
Eric Easom's compensation sits inside AN2 Therapeutics, Inc.'s full executive and board picture — the peer group, pay against peers, incentive design and the board itself.